Abbreviations: BSI=bloodstream infection; CENTRAL= central register of controlled trials); CVAD= central venous access device; CINAHL= cumulative index to nursing and allied health; CI = confidence interval; HD= hemodialysis; IR= incidence rate; MeSH=Medical subject headings; MOOSE= meta-analysis of observational studies in epidemiology; PICC=peripherally inserted central catheter; PRISMA= preferred reporting items for systematic reviews and meta-analyses; STROBE= strengthening the reporting of observational studies in epidemiology.
dysfunction [11] , with overall CVAD insertion-related complications reported in 7% to 18% of CVAD insertions. [12, 13 ] The more CVADs a child has previously had inserted, the more complex the procedure becomes, as CVAD failures can result in venous damage and insufficiency.
[12] Even after successful CVAD insertion, there are many mechanisms which may result in CVAD failure or complication, many of which are considered preventable. [14, 15] 
Infectious complications
CVADs place patients at risk of local and systemic infectious complications, including local site infection (e.g. exit site) and bloodstream infection (BSI). [5, 16] The multifocal path of microbial transmission of bacteria or fungi can be as a result of skin organisms at the insertion site, contamination of the internal device hub, hematogenous seeding and/or infusate contamination. [5, 17, 18 ] Microbial colonization of the entry or exit site of CVADs can result in local infection. This infection is commonly caused by resident skin flora, and results in inflammation of the skin (dermatitis), subcutaneous tissue (cellulitis) or vein (phlebitis). CVAD failure related to local infection is normally due to poor response to topical therapy, tunnel infection and purulent drainage.
[19]
CVAD-associated BSIs are prevalent world-wide, with an estimated 41,000 occurring in United
States hospitals each year.
[20] CVAD-associated BSI is associated with a prolonged hospital stay (~10 days) and an increase in the relative risk of death by 1.06 (absolute 1% attributable increase)
.
[21] CVAD-associated BSI have an attributable cost of between $5,821 and $60,536USD per event [22] [23] [24] and frequently result in device failure.
Mechanical complications
As CVADs remain partially exogenous to the body, CVAD failure may also occur as a result of dislodgement and breakage. Breakage of a CVAD is most commonly due to the use of excessive force, causing a split in the structure of the device. This may be due to drag from multiple heavy Page | 6 infusion tubes, catching on environmental structures (e.g. clothing, bedrails), intentional or accidental removal by patients or the use of inappropriately small syringe size for the injection of infusates. [3] CVAD occlusion may also result in device failure and is caused by the presence of a fibrin sheath, medication precipitate, catheter tip thrombus or position of the catheter tip against a vessel or chamber wall. [8, 25 ] CVAD-associated thrombosis may be as a result of fibrin deposited inside the CVADs (intraluminal thrombosis), adhering to the vein wall (mural thrombosis) or around the intravascular portion of the CVADs (fibrin sheath). [9, 25] Fibrin sheaths only cause malfunction when the sheath extends around or over the tip of the CVADs, and in many cases CVAD-associated thromboses are asymptomatic and the device continues to function. [25] Individual studies have examined the rate and incidence rate of CVAD failure and complications in pediatrics, but an overall estimation per CVAD type throughout this population has not been established. This systematic review aims to examine the proportion and rate of CVAD failure and complications in pediatrics across CVADs type.
Methods
The study used standard methods for systematic review and is reported in accordance with MOOSE (Meta-analysis of observational studies in epidemiology) [26] where applicable.
Eligibility criteria
A systematic search for cohort studies examining failure and complications of CVADs in pediatrics was conducted. Studies were eligible for inclusion if they met predefined inclusion criteria: (1) cohort design (prospective or retrospective); (2) study participants aged 0-18 years; (3) reported the failure and / or complications of CVADs included as outcome measures (4) reported the outcomes per PICCs, umbilical catheters, non-tunneled percutaneous CVADs, hemodialysis (HD) catheters, tunneled CVADs or totally implantable CVADs. The review was limited to observational studies in order to describe the failure and complications statistics across CVADs in pediatrics, without confounding the description with the comparative effectiveness of various interventions. There were no restrictions placed in terms of patient underlying condition. We excluded studies if they were not written in English and were greater than ten years old, to reflect and maximize relevance to current practices.
Outcome measures
The primary outcome of the review was defined a priori, in accordance with landmark intravascular research, as CVAD failure prior to the completion of necessary treatment.[27-29] The secondary outcomes were CVAD complications after successful CVAD insertion. These were:
1. CVAD-associated BSI: Minimum definition of a laboratory confirmed bloodstream infection that is not secondary to an infection at another body site, with a CVAD in place for greater than two days; [20] 2. CVAD-associated thrombosis: Development of thrombosed vessel (partial or complete) at the CVADs site diagnosed via ultrasound; [30] 3. Occlusion or blockage: As defined by study investigators and included partial and full blockage of the CVAD lumen or lumens, irrespective of occlusion treatment; [30] 4. Dislodgement or migration: As defined by study investigators and included partial, complete and accidental removal which results in the CVAD tip no longer being placed in the inferior or superior vena cava; [5] 5. Breakage or rupture: As defined by study investigators and included a visible split in CVADs material diagnosed by leakage or radiographic evidence of extravasation from a portion of the CVAD into tissue; [13] Additional studies were identified through searches of bibliographies.
Data extraction and missing data
All data were extracted by two independent investigators (AU, NM), using a standardized data extraction form. Study data were extracted regarding the number of patients, catheters, patient population, CVADs type, study method, frequency of CVAD failures and complications, catheter days and country of origin. For studies with missing data (e.g. CVAD catheter days), the study authors were contacted via email where possible.
Statistical methods
As only cohort studies were included, descriptive statistics have been used to provide summative information of the study population and results. Score confidence intervals (CI) with FreemanTukey double arcsine transformations were calculated for individual studies where the outcome was dichotomous (failure/no failure; binomial data), [31] and Poisson confidence intervals and standard errors were calculated for incidence rate (IR) outcomes. Pooled estimates were generated with random-effects meta-analysis, with results summarized per device type using proportion (%) and 95% CI. IR outcomes (continuous data) were pooled using inverse variance, with the DerSimonian and Laird method, per 1,000 catheter days and 95% CI. Heterogeneity (between studies) was assessed using the I 2 measure, categorized as low (<25%), moderate (25-75%) or high (>75%).
Subgroup analysis was completed with random-effects meta-regression. Subgroup analysis and tests for overall effect (null hypothesis: no treatment effect) were assessed with the P-value, categorized as significant at <0.05 level. Extreme or obviously incorrect data were re-checked for accuracy.
Stata [32] was used for all analyses.
Subgroup analysis
Given the predicted heterogeneity of the study populations, subgroup analyses were planned to compare CVAD failure rates by CVADs types in populations involving: neonates and pediatrics;
oncology / hematology and all others; and outpatient and inpatient managed devices. Results of the subgroup analyses are described using CVAD failure proportion, IR per 1,000 catheter days and 95% CI, where possible.
Risk of bias assessment and sensitivity analyses
In accordance with the MOOSE guidelines, 
Results

Systematic search results
Figure 1 describes the flow of inclusion and exclusion for the study selection, in accordance with the referred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.
[34] After removal of duplicates, 307 records were identified with 96 requiring full text for review.
From the full text articles, 22 were excluded as they included both adult and pediatric participants, and dislodgement data. These data were also not included in the review. We were unable to ascertain the number of catheter days in 23 studies, [66-82, 84, 85, 92, 97, 99, 122] which excluded their data from contributing to the meta-analysis reporting failure and complications per 1,000
catheter days. and the lowest proportion of breakage / rupture (0.0%, 95%CI 0.0-0.0; 2,179 CVAD).
Synthesis of results
CVAD failure
CVAD complications
Subgroup analyses
The results of the subgroup analyses describing the pooled proportion and IR of CVAD failure per 1,000 catheter days across study populations are shown in Table 3 . Due to availability of data, subgroup analyses were only carried out on PICCs (neonates and pediatrics; oncology/hematology and all others; outpatients and inpatients), tunneled CVADs (oncology/hematology and all others; outpatients and inpatients) and totally-implantable CVADs (oncology/hematology and all others). 
Sensitivity analyses
Discussion
This study has, for the first time, carefully found, critiqued and synthesized CVAD failure rates, across CVAD types and pediatric populations. The results clearly show that failure of CVADs throughout pediatrics is a substantial and significant problem, with one in four failing. This is especially prevalent within the lifespan of umbilical catheters and PICCs. These devices have been traditionally recommended for short to medium term use, [4, 6] but the PICCs and umbilical catheters described within the included studies failed prior to the completion of therapy in 11-30%
of cases, with a pooled incidence failure rate of 12-29 per 1,000 catheter days. This high rate of pediatric umbilical catheter and PICC failure is also evident in reported rates of catheter-associated BSI, occlusion, dislodgement and local infection/phlebitis. There is no previous umbilical catheter meta-analysis to benchmark these results and only small studies included within this review.
However our results in PICCs and recent studies by Chopra and colleagues in adults [126, 127] have demonstrated that PICCs are substantially more problematic than originally thought. The outcomes of PICCs used in clinical practice needs to be cautiously and systematically monitored.
Clinicians should be made aware of the high rates of failure associated with their use, and should question whether PICCs are the suitable intravascular device for their patient group. Research needs to be undertaken to discover and evaluate innovative strategies to reduce PICC and umbilical catheter failures, through examining insertion procedures, securement devices and patency practices.
Totally implanted devices were frequently associated with the lowest pooled incidence rate of failure and complications. These devices have previously been credited with improved ease of medication administration, decreased infectious risks and improved patient quality of life. [76] While the insertion of totally implanted and other tunneled CVAD requires the skills and resources of an experienced surgeon and operating theatre, fatal complications from cardiac tamponade and major vessel injury are rare. [10] It may be that due to lower rates of failure and complications, the cost-effectiveness of totally implanted devices is superior to other CVAD types for some population groups. Randomized controlled trials (RCTs) studying comparative clinical and cost-effectiveness of totally implanted devices, compared to other intravascular device types in suitable populations (e.g. cystic fibrosis) are urgently needed.
Given that many cases of CVAD failure and complications are thought to be avoidable, [6] the overall rate of CVAD failure and complication for children across all CVAD types appears variable, but remains unacceptably high. There are no current benchmarked targets for clinicians to compare their current rates of CVAD failure and complications, with the exception of CVAD-associated BSI in the ICU [128, 129] . Quality improvement studies have previously demonstrated a marked reduction in complication rates associated with CVAD in pediatrics and neonates, indicating that complication rates are dependent upon the care provided by multidisciplinary clinicians. [130] [131] [132] Previous international focus on the prevention of CVAD complications from organizations such as the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) has been solely focused on CVAD-associated BSI, and generally in the ICU setting. However, our data demonstrates that there is also a high rate of failure due to occlusion, thrombosis, breakage and dislodgement. The prevalence of thrombosis is likely to be higher than described, as some included studies relied upon clinical suspicion of thrombosis, rather than routine imaging, significantly underestimating the true proportion/rate of CVAD-related thrombosis. These mechanical complications also result in an interruption to necessary treatment and the insertion of new CVAD, and should be the focus of the next generation of multidisciplinary international CVAD campaigns for improvement.
The subgroup analyses demonstrated the variation in CVAD failure based upon patient age. The variation was most evident in comparisons involving PICCs, where neonates had a significantly higher rate of failure (p<0.001), than the remaining pediatric population, with a failure rate of 25.5
per 1,000 catheter days. PICCs are extensively used to provide hyperosmolar solutions, inotropic medicines and parenteral nutrition within the neonatal period. [124] The neonates requiring PICCs are often very low birth weight (smaller than 1,500g at birth) or extremely low birth weight (smaller than 1,000 g at birth), and are at greatest risk for failure and its sequelae. [60, 117] The increasing use of PICCs within the neonatal population requires caution and careful surveillance, and should be the focus of significant innovation for improvement.
Our study has demonstrated current gaps in the breadth and quality of research into pediatric CVAD failure and complications. Further prospective cohort studies estimating the rates of failure and complications of CVAD in pediatrics are necessary to provide benchmarking targets and inform practice innovations. Meta-synthesis of the two studies reporting non-tunneled CVAD failure reported a failure proportion of 16.7%, however no studies reported an estimation of catheter days.
In accordance with previous international focus, the majority of non-tunneled CVAD studies which reported CVAD complications only reported CVAD-associated BSI. The failure and complications associated with HD and umbilical catheters were also inadequately reported, with only six studies of 749 CVADs available. Considering the prevalence and importance of umbilical, HD and nontunneled CVADs within pediatric healthcare management, reliable measurement of their failure and complications are essential. Additionally, while multiple cohort studies described the failure of PICCs and totally implanted devices, the majority used retrospective methods, using less reliable means of data collection. Future descriptions of CVAD failure need to be planned prospectively, use validated definitions for outcome measures and report denominator information including catheter days.
Our study results should be interpreted in the context of some limitations. Not all study authors were able to provide the total number of catheter days, which limited their data being included in the meta-analysis per 1,000 catheter days. Such time-based analysis is the more valid way to compare CVAD complication incidence, since the different dwell times typical of the CVAD types already exposes the patient to more or less risk of complications. Secondly, the unavoidable heterogeneity of the study populations in the included studies may have impacted on the generalizability of the results, subgroup analyses were used to reduce this problem. The levels of statistical heterogeneity of the final analyses are indicative of the heterogeneous group of pediatric patients which require CVADs. This heterogeneity needs to be recognized before applying the results to local individual healthcare institutions. Thirdly, while our review was limited to include studies up to ten years of age, many quality improvement activities have been instituted in pediatric facilities to prevent complications and failures associated with CVAD within that period. It is therefore possible that the pooled data may therefore overestimate the burden of device failure in 2015. Finally, while our study presents the association between CVAD-types and failure and complications, these results do not reflect causation. Without RCTs comparing the various CVAD types, it is impossible to assert that one CVAD type reduces complications and failure in comparison to another. Future updates of this review may also consider the inclusion of the 'standard care' arm of RCTs which evaluated various interventions.
Comparison with other studies
There has not been a previous systematic review undertaken in pediatrics examining the failure and complications associated with different CVADs. Landmark work by McGee and Gould [133] described the prevention, treatment and incidence of CVAD failure in the adult population. While primarily focused on describing strategies to prevent and treat CVAD complications, their systematic review reported an overall incidence of CVAD failure of greater than 15%, with mechanical complications reported in 5% to 19% of patients, and infectious complications in 5 to 26%. Our study describes a higher rate of mechanical and infectious complications which may be due to differing synthesis methodology and the underlying vulnerability and other clinical characteristics of the population studied.
Conclusion and future research
International healthcare institutions have highlighted the significance of CVAD failure associated with BSI. This systematic review has described the broader, multi-focal rate of CVAD failure and complications across CVAD type in pediatrics within the international healthcare community.
Contextually, from the 82 US hospitals reporting to the National Healthcare Safety Network in 2013, greater than 2.7 million CVAD catheter days in the pediatric and neonatal population were registered. [134] Applying the rate of failure described in our study, 5,457 pediatric and neonatal CVADs in US hospitals failed prior to completion of treatment in one year alone. These failures place a massive economic and physical burden on the US healthcare system, patients and families. Research is required urgently to develop and apply innovative and effective solutions to prevent CVAD failure in this vulnerable pediatric group.
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